April, 2024 - Dr. Marusak is promoted to Associate Professor with tenure. Congratulations on this major stepping stone!
Dec 11, 2023 – Dr. Greenwald presents in joint federal agency (SAMHSA/NIDA/FDA) sponsored virtual roundtable meeting on the need for high-dose buprenorphine in the era of high-potency synthetic opioids.
Dec 5, 2023 – Dr. Woodcock participates in Q&A forum on addiction, hosted by the WSU Student Senate Mental Health Project Group.
May 19, 2023 - Dr. Greenwald presents with Drs. Gail D’Onofrio and Kate Hawk (Yale University), and Andrew Herring (Alameda Hospital, Oakland CA) on panel at the Society for Academic Emergency Medicine, “Buprenorphine in the era of fentanyl: truths, trends and treatments”.
May 2023 - Monya Ali joins DrugLab as a research assistant, after having served as an undergraduate research volunteer. Welcome Monya!
May, 2023 (effective Aug 2023) – Dr. Lundahl is promoted to Full Professor. Congratulations on this huge accomplishment!
April 19, 2023 - Dr. Greenwald gives Psychiatry Grand Rounds, “Cannabinoids for the treatment of pain: Real deal or smoke and mirrors?”
April 13, 2023 - Dr. Greenwald gives invited talk to ASAM Addiction & Pain Common Threads pre-conference course, “The latest on buprenorphine – pharmacology, formulations, and misconceptions”.
March, 2023 - Taylor Harrison joins DrugLab as a research assistant, after having served as a research volunteer. Welcome Taylor!
Nov, 2022 – Cecilia Li joins DrugLab as a research assistant. Welcome Cecilia!
Sept 6, 2022 - Dr. Greenwald gives invited virtual talk at NIDA Clinical Trials Network meeting, “Prehospital treatment for opioid use disorder”.
July 18, 2022 - Alyson Renock joins DrugLab as RA - welcome Alyson!
July 15, 2022 - Klevis Karavidha’s last day (say it ain’t so!) But we’re looking forward to seeing him succeed in medical school at Michigan State University! And we’re thankful that Alanna will continue to work with us!
July 13, 2022 - Dr. Leslie Lundahl and Dr. Christine Rabinak awarded $9 million, 5-year State of Michigan LARA grant titled, Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure Therapy and Recovery (CAPER). Co-Investigators: Drs. David Ledgerwood, Hilary Marusak and Mark Greenwald
July 13, 2022 - Dr. Eric Woodcock and Dr. Hilary Marusak awarded $3.5 million State of Michigan LARA grant supplement titled, “Investigating the Therapeutic Impact of Cannabinoids on Neuroinflammation and Neurobiological Underpinnings of Suicide Ideation in Veterans with PTSD”.
June 29, 2022 - Pre-recorded broadcast of Dr. Greenwald presenting to US addiction medicine healthcare providers, “The neurobiology of addiction: challenging what we know”, following by livestream Q&A session (150 attendees nationally)
June, 2022 - CPDD conference: Dr. Greenwald served as Chair of a genetics session and gave oral presentation titled, “Mu-opioid receptor epigenetics in persons with opioid use disorder: a pilot study”. Dr. Greenwald also moderated discussion in a separate symposium on the orexin system. Other posters were presented by the team (Ciara Cannoy, Tabitha Moses, Dr. Ledgerwood, and Dr. Lundahl).
May 2022 - Alanna Foulon joins DrugLab as RA - welcome Alanna!
April 27, 2022 - Tabitha Moses receives Dept. of Psychiatry Asselin award for the best student paper. Congratulations, Tabitha!
April 2022 - Detroit vs. Addiction publishes paper in Journal of Addictive Diseases on the development of this medical student organization!
April 2022 - Frances (Fran) Bausano and Jasmine Hollins join DrugLab as RAs - welcome!
March 27, 2022 – Dr. Greenwald invited talk to American Society on Clinical Psychopharmacology, “Psychopharmacological management of opioid use disorder in the era of fentanyl”, Los Angeles, CA
October 2021 - Dr. Greenwald receives contract from NET Recovery Corp. to conduct a randomized, sham-controlled, FDA-qualifying clinical trial of a new medical device (NeuroElectric Therapy) for treatment of opioid use disorder. The trial starts November 8 in Kentucky at the treatment facility Isaiah House. See Wayne State press release.
September 2021 - Reshma Dukkipati joins DrugLab as RA - welcome!
Krithika Prakash joins DrugLab as Clinical Psychology practicum student - welcome!
Dr. Greenwald receives 3-year NIDA award (R33 DA044946) to continue ongoing research program in opioid/benzodiazepine polysubstance use. See Wayne State press release.
Lead PI Dr. Erin Madden (Family Medicine and Public Health Sciences) and Co-PI Dr. Greenwald receive 3-year NIDA award (R34 DA053758) to plan a multi-level intervention to reduce stigmatizing attitudes and behavior among healthcare professionals in the context of HIV and substance use care. See Wayne State press release.
August 2021 - Dr. Lundahl leads a team of Dept. of Psychiatry and Behavioral Neurosciences investigators (including Co-PI Dr. Norrholm, and Co-Investigators Drs. Ledgerwood, Greenwald, Marusak and Jovanovic) in receiving a $7 million, 5-year award from the State of Michigan Dept. of Licensing and Regulatory Agency (LARA). This large-scale project will undertake clinical trials and laboratory studies on the efficacy of cannabis constituents ∆9-THC and CBD in reducing PTSD symptoms and suicidality in U.S. military veterans. See Wayne State press release and listen to Dr. Lundahl’s Today@Wayne podcast interview.
August 5, 2021 - Drs. Greenwald, Warren Bickel (Virginia Tech Carilion Institute), Tipu Khan (UCLA), and Laura Kehoe (Harvard): presentation and panel discussion webcast, “Dialogue on the neurobiology of OUD: Applying brain science to treatment decisions and behavior change”
August 2, 2021 - Anju Thomas joins DrugLab as full-time Research Assistant - welcome!
July 26, 2021 - Klevis Karavidha returns to DrugLab as full-time Research Assistant - welcome!
February 2021 - Dr. Greenwald gives Psychiatry Grand Rounds, “Stress-reactive substance use: concepts, mechanisms, and therapeutic prospects”. View the recording here: https://wayne-edu.zoom.us/rec/share/9IsI1nUyv2xW9MurZ24FXN8ZFeTEUOYgdTrV9mGVLgua2bgP-amifZI-o2YtCaa_.3ZcuUAezWcSUnSmE
September 2020 - Pre-recorded broadcast of Dr. Greenwald presenting to US addiction medicine healthcare providers, “The neurobiology of addiction: challenging what we know”, following by livestream Q&A session (> 360 attendees nationally)
September 2020 - Livestream real-time broadcast of Dr. Greenwald presenting to US addiction medicine healthcare providers, “The neurobiology of addiction: challenging what we know” (> 400 attendees nationally)
August 2020 - Livestream real-time broadcast of Dr. Greenwald presenting to Australian addiction medicine healthcare providers, “Buprenorphine extended-release (BUP-XR) in opioid use disorder: its foundation and promise” (> 330 live attendees, with recording distributed to > 800 registrants)
February 2020 – Dr. Greenwald speaks to Wayne County Families Against Narcotics (FAN) Network, “The science of addiction”
January 2020 – Dr. Greenwald speaks to WSU medical student section of the Michigan State Medical Society, “Opioid use disorder and overdose: what to know, what to do”
November 2019 – Dr. Greenwald gives invited keynote talk to Michigan Society of Addiction Medicine (MISAM) annual meeting (Yspilanti), “What clinicians need to know about buprenorphine for treatment of opioid use disorder”
October 2019 – Dr. Greenwald speaks to addiction medicine physicians in Stockholm (Sweden), Biarritz (France), Helsinki (Finland), and Milan (Italy)
August 2019 – Dr. Greenwald presents to Detroit vs. Addiction medical students, “Advances and challenges in addressing epidemic substance use-related problems”
April 2019 – Dr. Greenwald presents invited talk at the WSU Integrated Biosciences Center (IBio), “Stress at the crossroads of addiction and pain: mechanisms and therapeutic opportunities”
March 2019 – Dr. Greenwald talks and participates on discussion panel at the University of Michigan, “(Endo)cannabinoid therapeutic potential”
February 2019 - Dr. Greenwald publishes paper on depot buprenorphine injections in The Lancet: Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
February 2019 – Dr. Greenwald gives invited talk to WSU College of Nursing, “The promise and perils of cannabinoid therapeutics”
October 2018 – Dr. Greenwald gives Psychiatry Grand Rounds, “Scientific development of extended-release buprenorphine, and its clinical importance for treatment of opioid use disorder”
September 2018 – Dr. Greenwald speaks to addiction medicine physicians in Montreal, Ontario, London and Toronto, Canada
August 2018 – Dr. Greenwald speaks to addiction medicine physicians in Calgary (Alberta) and Vancouver (British Columbia), Canada
June 2018 – The Drug Lab headed to San Diego to present at The College on Problems of Drug Dependence 80th Annual Scientific Meeting and gave 2 presentations and 5 posters:
Heroin delay discounting and impulsivity: modulation by DRD1 genetic variation.
Variants in stress-signaling genes NR3C1 and FKBP5 modulate opioid abstinence during buprenorphine (BUP) stabilization and dose tapering.
Effects of smoked cannabidiol on cardiovascular, subjective and reinforcing effects of smoked THC.
Differences associated with injection drug use (IDU) vs. non-IDU among Black heroin users in an urban setting.
Post-birth treatment outcomes in pregnant, methadone-maintained women.
Dimensions of negative consequences in regular marijuana users differ by sex
Clinical and personality characteristics of problem and pathological gamblers with and without symptoms of adult ADHD
March 2018 – Dr. Ledgerwood elected as Secretary for the Michigan Association on Problem Gambling